Despite notable strides in drug development, the biopharma sector continues to grapple with the twin burdens of high costs and lengthy timelines associated with research and development (R&D) endeavors. The emergence of AI-driven methodologies in drug discovery has heralded a transformative shift in this landscape, catalyzed by a surge in market entrants, substantial capital injections, and the maturation of technological capabilities.

Over the past decade, investment in AI-driven drug discovery has experienced exponential growth, underpinned by the relentless pursuit of innovation and efficiency gains. Notably, recent breakthroughs in generative AI and the advent of large language models (LLMs) such as ChatGPT have further augmented the potential of AI to revolutionize drug discovery paradigms.

In this presentation, Dr. Wang will embark on a concise exploration of the burgeoning realm of AI-enabled drug discovery, delving into the exhilarating prospects it offers while candidly addressing the inherent challenges. By elucidating the transformative power of AI in reshaping drug discovery processes, we aim to provide insights into the pivotal role of cutting-edge technologies in accelerating pharmaceutical innovation and enhancing patient outcomes.